Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinatuzumab vedotin or polatuzumab vedotin with anti-CD20 antibody in relapsed or refractory B-cell non-Hodgkin lymphoma
2011-004377-84Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in mature B-cell lymphoma, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) comparing Pinatuzumab vedotin + rituximab, Polatuzumab vedotin + rituximab and Polatuzumab vedotin + obinutuzumab (3 arms). Primary endpoint: Safety. Started Oct 2012; status: completed.
02
Drugs
pinatuzumab vedotinpolatuzumab vedotinrituximabobinutuzumab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-004377-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004377-84.